Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome

被引:13
|
作者
Szejko, Natalia [1 ,2 ]
Fichna, Jakub Piotr [3 ]
Safranow, Krzysztof [4 ]
Dziuba, Tomasz [1 ]
Zekanowski, Cezary [3 ]
Janik, Piotr [1 ]
机构
[1] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Bioeth, Warsaw, Poland
[3] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Neurodegenerat Disorders, Lab Neurogenet, Warsaw, Poland
[4] Pomeranian Med Univ, Dept Biochem & Med Chem, Szczecin, Poland
关键词
Gilles de la Tourette syndrome; endocannabinoids; association study; CNR1; gene; CB1cannabinoid receptor 1; DELTA(9)-TETRAHYDROCANNABINOL THC; ENDOCANNABINOID SYSTEM; POLYMORPHISMS; DISORDER; THERAPY; OBESITY; IMPULSIVITY; IMPACT; INDEX; RISK;
D O I
10.3389/fgene.2020.00125
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Gilles de la Tourette syndrome (GTS) is a neuropsychiatric disorder of unknown etiology, although a major role of genetic factors has been established. Cannabis-based medicines may alleviate GTS-associated tics and variants of CNR1 gene encoding central cannabinoid receptor (CB1) are believed to be a risk factor for the development of some neurodevelopmental diseases. Our aim was to test the association of selected CNR1 gene variants with GTS. Material and Methods The cohort of GTS cases comprised 262 unrelated patients aged 3-53 years (mean age: 18.3 +/- 9.1 years; 204 males (77.9%), 126 (48.1%) adults defined as >= 18 years). As a control group we enrolled 279 unrelated, ethnically and gender matched individuals with no diagnosed mental, neurological or general disorder, aged 13-54 years (mean age: 22.5 +/- 3.0 years; 200 males, (74.1%). Both study and control groups were selected from Polish population, which is ethnically homogenous subgroup of Caucasian population. Four single nucleotide polymorphisms (SNPs) in CNR1 were selected: rs2023239, rs2180619, rs806379, and rs1049353 based on minor allele frequency in general population >15%. These variants were genotyped using a real-time quantitative polymerase chain reaction system (TaqMan SNP genotyping assay). Results We found significant association of GTS clinical phenotype with rs2023239 variant. Minor allele C and CT+CC genotypes were found significantly more often in GTS patients compared to controls (17.4 vs 11.1%, p=0.003 and 32.8 vs 20.4%, p=0.001, respectively), and the difference remained significant after correction for multiple testing. C allele of rs2023239 polymorphism of the CNR1 gene was associated with the occurrence of tics. There were no statistically significant associations for rs806379, rs1049353 or rs2180619 variants. Conclusion Our findings suggest that C allele of rs2023239 polymorphism of the CNR1 gene is a risk factor of GTS in Polish population. The variant can be potentially associated with abnormal endocannabinoid transmission, which is suspected to be one of the causes of GTS.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population
    Isabel Martínez-Gras
    Janet Hoenicka
    Guillermo Ponce
    Roberto Rodríguez–Jiménez
    Miguel Angel Jiménez-Arriero
    Elena Pérez-Hernandez
    Israel Ampuero
    Jose Antonio Ramos-Atance
    Tomas Palomo
    Gabriel Rubio
    European Archives of Psychiatry and Clinical Neuroscience, 2006, 256 : 437 - 441
  • [22] Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder
    Peiro, Ana M.
    Garcia-Gutierrez, Maria S.
    Planelles, Beatriz
    Femenia, Teresa
    Mingote, Carlos
    Jimenez-Trevino, Luis
    Martinez-Barrondo, Sara
    Garcia-Portilla, M. Paz
    Saiz, Pilar A.
    Bobes, Julio
    Manzanares, Jorge
    ANXIETY STRESS AND COPING, 2020, 33 (03): : 256 - 265
  • [23] Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal
    Evans, D. E.
    Sutton, S. K.
    Jentink, K. G.
    Lin, H. -Y.
    Park, J. Y.
    Drobes, D. J.
    GENES BRAIN AND BEHAVIOR, 2016, 15 (07) : 621 - 626
  • [24] Association study of Gilles de la Tourette Syndrome with variants of the IL-10 receptor 1
    Schosser, A
    Aschauer, HN
    Schloegelhofer, M
    Leisch, F
    Stamenkovic, M
    Hornik, K
    Gasche, C
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2004, 130B (01): : 101 - 102
  • [25] The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults
    Hartman, Christie A.
    Hopfer, Christian J.
    Haberstick, Brett
    Rhee, Soo Hyun
    Crowley, Thomas J.
    Corley, Robin P.
    Hewitt, John K.
    Ehringer, Marissa A.
    DRUG AND ALCOHOL DEPENDENCE, 2009, 104 (1-2) : 11 - 16
  • [26] Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia
    Chavarria-Siles, Ivan
    Contreras-Rojas, Javier
    Hare, Elizabeth
    Walss-Bass, Consuelo
    Quezada, Paulina
    Dassori, Albana
    Contreras, Salvador
    Medina, Rolando
    Ramirez, Mercedes
    Salazar, Rodolfo
    Raventos, Henriette
    Escamilla, Michael A.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2008, 147B (03) : 279 - 284
  • [27] CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
    H Ujike
    M Takaki
    K Nakata
    Y Tanaka
    T Takeda
    M Kodama
    Y Fujiwara
    A Sakai
    S Kuroda
    Molecular Psychiatry, 2002, 7 : 515 - 518
  • [28] A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene
    Gadzicki, D
    Müller-Vahl, K
    Stuhrmann, M
    MOLECULAR AND CELLULAR PROBES, 1999, 13 (04) : 321 - 323
  • [29] GILLES-DE-LA-TOURETTE-SYNDROME ASSOCIATION
    不详
    NEUROLOGY, 1976, 26 (04) : 398 - 398
  • [30] Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence
    Okahisa, Y.
    Kodama, M.
    Takaki, M.
    Inada, T.
    Uchimura, N.
    Yamada, M.
    Iwata, N.
    Iyo, M.
    Sora, I.
    Ozaki, N.
    Ujike, H.
    CURRENT NEUROPHARMACOLOGY, 2011, 9 (01) : 183 - 189